When severe nerve pain turns the body's alarm system into an unceasing siren, can just five days of intravenous ketamine force the brain to unlearn the agony? We dive into a head-to-head clinical trial pitting ketamine against lidocaine to uncover how a rapid molecular circuit breaker delivers months of life-changing relief.
### Engaging Description
When severe neuropathic pain turns the nervous system into an unceasing alarm, conventional daily medications fail over half of all sufferers. In a head-to-head clinical trial, researchers pitted five consecutive days of intravenous ketamine directly against lidocaine to discover which could halt treatment-resistant nerve pain faster.
Ketamine emerged as an explosive sprinter, delivering clinically meaningful relief in over 86% of patients by week two compared to just 50% for lidocaine. Remarkably, both therapies converged at a 60% sustained success rate by six months, highlighting critical trade-offs between central and peripheral pathways. Tune in to discover how targeted infusions can disrupt entrenched pain circuits and restore lasting hope.
Resources:
Sucu, M. G., Yavuz Mollavelioğlu, T., Akyüz Yildirim, A., & Çelebi, N. (2026). Short- and midterm analgesic outcomes of ketamine versus lidocaine infusion in chronic peripheral neuropathic pain: A retrospective study. Pain Research and Management, 2026, Article 7897619. https://doi.org/10.1155/prm/7897619
Podden och tillhörande omslagsbild på den här sidan tillhör
Talking Ketamine. Innehållet i podden är skapat av Talking Ketamine och inte av,
eller tillsammans med, Poddtoppen.
